GUMULEC, Jaromír, Michal MASAŘÍK, S. KŘÍŽKOVÁ, P. BABULA, Roman HRABEC, Arne ROVNÝ, M. MASAŘÍKOVÁ, V. ADAM, T. ECKSCHLAGER and René KIZEK. Bioanalytické studium nádorových markerů karcinomu prostaty na úrovni RNA a proteinu (Bioanalytical study of tumour markers for prostate carcinoma at RNA and protein level). Praktický lékař. 2011, vol. 91, No 8, p. 469–474, 5 pp. ISSN 0032-6739.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Bioanalytické studium nádorových markerů karcinomu prostaty na úrovni RNA a proteinu
Name (in English) Bioanalytical study of tumour markers for prostate carcinoma at RNA and protein level
Authors GUMULEC, Jaromír (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution), S. KŘÍŽKOVÁ (203 Czech Republic), P. BABULA (203 Czech Republic), Roman HRABEC (203 Czech Republic, belonging to the institution), Arne ROVNÝ (203 Czech Republic, belonging to the institution), M. MASAŘÍKOVÁ (203 Czech Republic), V. ADAM (203 Czech Republic), T. ECKSCHLAGER (203 Czech Republic) and René KIZEK (203 Czech Republic).
Edition Praktický lékař, 2011, 0032-6739.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/11:00049972
Organization unit Faculty of Medicine
Keywords (in Czech) nádorová onemocnění; polymerázová fietúzová reakce; elektrochemie; imunodetekce; molekulárně- biologické techniky; nádorové markery
Keywords in English tumour diseases; polymerase chain reaction; electrochemistry; immunodetection; molecularly-biological techniques; tumour markers
Tags Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 15/9/2011 12:56.
Abstract
Současné možnosti diagnostiky karcinomu prostaty neumožňují odlišit agresivní (signifikantní tumory) od klinicky latentních (nesignifikantních forem). Práce se zaměřuje na stanovení hladiny klinicky využitelných tumorových markerů karcinomu prostaty: - alfa-metyl CoA-racemáza (AMACR), - caveolin-1, - metalothionein (MT), - p53, - NF-kB, - c-FOS, - c-JUN, - Ki-67, - prostatický specifický antigen (PSA), - ZIP1 a ZnT-1 na úrovni prostatické tkáně (reprezentované buněčnými liniemi 22Rv1 a PNT1A) a v séru pacientů s histologicky ověřeným adenokarcinomem (82 karcinomových a 51 kontrolních sér). Na úrovni mRNA bylo zjištěno snížení exprese Cav-1, NF-kB, c-FOS a c-JUN a zvýšení exprese metalothioneinu, AMACR, PSA, Ki-67, MMP-9 a zinkových transportérů ZIP1 a ZnT-1. V séru je popsáno signifikantní zvýšní metalothioneinu nad hladinu 1 mikroM. Hladina caveolinu-1 se významně zvyšuje u high-grade tumorů, což jej staví do pozice možného markeru agresivní formy karcinomu prostaty.
Abstract (in English)
Current methods for diagnosis of prostate carcinoma do not enable us to distinguish aggressive tumours (significant tumours) from clinically latent tumours (non-significant tumours). This study aims to determine levels of potential clinically important tumour markers such as - alpha-methyl CoA-racemase (AMACR), - caveolin-1, - metallothionein (MT), - p53, - NF-kB, - c-FOS, - c-JUN, - Ki-67, - prostate-specific antigen (PSA), ZIP1 and ZnT-1 in prostatic tissue represented by 22Rv1 (tumour) and PNT1A (healthy) cell lines and in blood serum of patients with histologically evaluated adenocarcinoma (82 tumour patients and 51 healthy volunteers). Based on mRNA expression, it was found that Cav-1, NF-kB, c-FOS and c-JUN were down-regulated and MT,AMACR, PSA, Ki-67, MMP-9 and zinc transporters ZIP1 and ZnT-1 were up-regulated. In serum, the level of MT was significantly enhanced above 1 microM. Caveolin-1 levels were significantly increased in high-grade tumours, which points to the possibility of using this protein as a marker for the aggressive form of prostate carcinoma.
Links
GP301/09/P436, research and development projectName: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.
Investor: Czech Science Foundation
NS10200, research and development projectName: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty
Investor: Ministry of Health of the CR
PrintDisplayed: 15/7/2024 18:55